Skip to main content
. Author manuscript; available in PMC: 2016 Mar 4.
Published in final edited form as: Inflamm Bowel Dis. 2013 Mar;19(3):621–626. doi: 10.1097/MIB.0b013e31827eea78

Figure 2.

Figure 2

Survival analysis of fistulizing and non-fistulizing patients among 12 months responders and non-responders. Time to discontinuation of natalizumab treatment was analyzed using Kaplan-Meier estimator as in figure 1 in the two groups. Patients with non-fistulizing disease were significantly more likely to respond to natalizumab (log-rank p = 0.031).